

INTERNATIONAL SEARCH REPORT

International Application No
PCT/FR 03/00007

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/53 C12Q1/68 C12N15/11 A61K31/7105

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC.7 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, EMBASE, WPI Data, PAJ, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIRCHENALL-ROBERTS M C ET AL: "Inhibition of murine monocyte proliferation by a colonystimulating factor-1 antisense oligodeoxynucleotide" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 145, no. 10, 15 November 1990 (1990-11-15), pages 3290-3296, XP002957654 ISSN: 0022-1767 the whole document --- -/-	1-33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

16 September 2003

Date of mailing of the international search report

23.10.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rojo Romeo, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/ 03/00007

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	AHARINEJAD SEYEDHOSSEIN ET AL: "Colony-stimulating factor-1 antisense. treatment suppresses growth of human tumor xenografts in mice." CANCER RESEARCH, vol. 62, no. 18, 15 September 2002 (2002-09-15), pages 5317-5324, XP002247522. September 15, 2002 ISSN: 0008-5472 the whole document	1-33
X	WO 01 30381 A (AHARINEJAD SEYEDHOSSEIN ;HOFBAUER REINHOLD (AT)) 3 May 2001 (2001-05-03) the whole document	15-33
X	DATABASE EMBL 'Online! 2 September 1990 (1990-09-02) WONG ET AL.: "Human macrophage-specific colony-stimulating factor (CSF-1) mRNA, complete cds" retrieved from EBI Database accession no. M37435 XP002254237 abstract	15-29
X	KESHAHA N ET AL: "Blocking of colony stimulating factor expression with antisense RNA in breast and ovarian cancer epithelial cells leads to programmed cell death" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 38, 1997, page 500 XP002165344 ISSN: 0197-016X the whole document	15-33
X	KESHAHA N ET AL: "Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis." JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION. UNITED STATES 1999 JAN-FEB, vol. 6, no. 1, January 1999 (1999-01), pages 41-49, XP002254236 ISSN: 1071-5576 voir en particulier le dernier paragraphe de la page 45.	15-33

-/--

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/FR 93/00007

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE" CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543-584, XP000141412 ISSN: 0009-2665 voir en particulier Part VI. the whole document</p> <p>-----</p>	

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/03/00007

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0130381	A	03-05-2001	WO 0130381 A2	03-05-2001
			AT 240744 T	15-06-2003
			AU 1114501 A	08-05-2001
			CA 2388298 A1	03-05-2001
			DE 50002293 D1	26-06-2003
			DK 1223980 T3	15-09-2003
			EP 1223980 A2	24-07-2002

BEST AVAILABLE COPY

The International Searching Authority has determined that this international application contains more than one invention or group of inventions, namely

Invention 1: Claims 1-14, 30,
31 (in full), 32 (in part)

Product resulting from the combination of at least one substance capable of inhibiting CSF-1 activity and at least one substance having at least one cytotoxic activity; composition including at least one such combination product; and the use thereof.

Invention 2: Claims 15-29,
33 (in full), 32 (in part)

Oligonucleotide 8 to 100 nucleotides long capable of inhibiting CSF-1 expression, characterised in that it is capable of hybridizing with the region between the nucleotide in position 121 and the nucleotide in position 450, inclusive, of SEQ ID NO 1, the nucleotide in position 131 and the nucleotide in position 391, inclusive, of SEQ ID NO 1, the nucleotide in position 135 and the nucleotide in position 152, inclusive, of SEQ ID NO 1, the nucleotide in position 284 and the nucleotide in position 301, inclusive, of SEQ ID NO 1, the nucleotide in position 341 and the nucleotide in position 358, inclusive, of SEQ ID NO 1; nucleic acid coding for said oligonucleotide; composition including said oligonucleotide; and the use thereof.

Invention 3: Claim 32 (in part)

Use of a substance capable of inhibiting CSF-1 activity and not covered by inventions 1 and 2 for preparing a drug for enhancing the effectiveness of an antitumour treatment.